Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
14
×
deals
14
×
life sciences
national blog main
biotech
boston
national top stories
clinical trials
san francisco blog main
san francisco top stories
startups
fda
new york blog main
new york top stories
sanofi
alexion pharmaceuticals
alnylam pharmaceuticals
boehringer ingelheim
eli lilly
hepatitis b
investing
rna interference
roche
vc
amgen
autoimmune disorders
crispr
gene editing
genentech
glaxosmithkline
ipo
san francisco
third rock ventures
warp drive bio
abbvie
acetylon pharmaceuticals
alirocumab
allergan
allosteric
What
medicines
14
×
drug
new
deal
disease
research
biotech
cancer
gene
pharma
adds
ago
alliance
bio
called
candidate
companies
company
dicerna
diseases
editing
fda
hepatitis
molecules
pact
pharmaceuticals
potential
rna
roche
stakes
startup
synthetic
targets
team
therapeutics
vaccines
years
abandoning
abbvie
acquire
Language
unset
Current search:
deals
×
medicines
×
" boston top stories "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines